Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are: * Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment? * What medical problems do participants have when receiving axi-cel treatment? In this investigator-initiated, single-arm clinical trial, participants will: * Receive atezolizumab treatment at 2.0×10\

Trial Details

NCT ID

NCT06609304

Phase

PHASE4

Sponsor

Zhengzhou University

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Axicabtagene Ciloleucel

Locations (sample)

• Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

• Understand and voluntarily sign the informed consent form;
• 18-70 years of age (inclusive);
• Previously untreated CD19-positive large B-cell lymphoma;
• Anticipated survival ≥12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →